Overview of Chemistry and Therapeutic Potential of Non-Nitrogen Heterocyclics as Anticonvulsant Agents by Pal, Rohit, Singh, Karanvir, Paul, Joyson, Khan, Shah Alam, Naim, Mohd Javed, Akhtar, Md Jawaid

Get full text

Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors by Arbour, Kathryn C, Naidoo, Jarushka, Steele, Keith E, Ni, Ai, Moreira, Andre L, Rekhtman, Natasha, Robbins, Paul B, Karakunnel, Joyson, Rimner, Andreas, Huang, James, Riely, Gregory J, Hellmann, Matthew D

Get full text

Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker... by Friedman, Claire F, Spencer, Christine, Cabanski, Christopher R, Panageas, Katherine S, Wells, Daniel K, Ribas, Antoni, Tawbi, Hussein, Tsai, Katy, Postow, Michael, Shoushtari, Alexander, Chapman, Paul, Karakunnel, Joyson, Bucktrout, Samantha, Gherardini, Pier, Hollmann, Travis J, Chen, Richard O, Callahan, Margaret, LaVallee, Theresa, Ibrahim, Ramy, Wolchok, Jedd

Get full text

The REstart or STop Antithrombotics Randomised Trial (RESTART) after stroke due to intracerebral haemorrhage: study protocol for a randomised controlled trial by Al-Shahi Salman, Rustam, Dennis, Martin S, Murray, Gordon D, Innes, Karen, Drever, Jonathan, Dinsmore, Lynn, Williams, Carol, White, Philip M, Whiteley, William N, Sandercock, Peter A G, Sudlow, Cathie L M, Newby, David E, Sprigg, Nikola, Werring, David J

Get full text

Reasons for non-recruitment of eligible patients to a randomised controlled trial of secondary prevention after intracerebral haemorrhage: observational study by Maxwell, Amy E, MacLeod, Mary Joan, Joyson, Anu, Johnson, Sharon, Ramadan, Hawraman, Bellfield, Ruth, Byrne, Anthony, McGhee, Caroline, Rudd, Anthony, Price, Fiona, Vasileiadis, Evangelos, Holden, Melinda, Hewitt, Jonathan, Carpenter, Michael, Needle, Ann, Valentine, Stacey, Patel, Farzana, Harrington, Frances, Mudd, Paul, Emsley, Hedley, Gregary, Bindu, Kane, Ingrid, Muir, Keith, Tiwari, Divya, Owusu-Agyei, Peter, Temple, Natalie, Sekaran, Lakshmanan, Ragab, Suzanne, England, Timothy, Hedstrom, Amanda, Jones, Phil, Jones, Sarah, Doherty, Mandy, McCarron, Mark O, Cohen, David L, Tysoe, Sharon, Al-Shahi Salman, Rustam

Get full text

Abstract A046: Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 in patients with glioblastoma (GBM) by Reardon, David A., Dietrich, Jorg, Kaley, Thomas, Gan, Hui, Dunn, Gavin P., Cloughesy, Timothy, Lim, Michael, Clarke, Jennifer, Park, Andrew, Pan, Linda, Lai, Domenic W., Karakunnel, Joyson, Robbins, Paul, Narwal, Rajesh, Venhaus, Ralph

Get full text

Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic... by Kelly, Ronan J, Chung, Ki, Gu, Yu, Steele, Keith E, Rebelatto, Marlon C, Robbins, Paul B, Tavakkoli, Fatemeh, Karakunnel, Joyson J, Lai, Dominic W, Almhanna, Khaldoun

Get full text

A Phase I study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) in combination with tremelimumab in patients with advanced solid tumors by Papadopoulos, Kyriakos P, Tsai, Frank, Hamid, Omid, Xiao, Feng, Steele, Keith E, Rebelatto, Marlon C, Robbins, Paul B, Karakunnel, Joyson J, Lai, Dominic W, Mahipal, Amit

Get full text

Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung canc... by Brahmer, Julie, Balmanoukian, Ani, Goldberg, Sarah, Ou, Sai-Hong, Blake-Haskins, Andrew, Karakunnel, Joyson, Stockman, Paul, Rizvi, Naiyer, Antonia, Scott

Get full text